Project Grant R01CA315977
Award Date 8/14/26
Completion Date 7/31/31
Dollars Obligated $786K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Cancer Institute awarded Cedars-Sinai Medical Center $695,634 under the Cancer Biology Research program (CFDA 93.396) on May 7, 2026, to investigate the role of interleukin-27 receptor signaling in B cell immune responses within hepatocellular carcinoma tumor microenvironments. The research aims to identify new immunotherapy mechanisms and biomarkers for liver cancer treatment, building on the recipient's laboratory findings that IL27R signaling suppresses anti-cancer natural killer...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $708,990 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate microenvironmental and hepatocyte cell type-specific regulation of colorectal cancer metastasis by IL17 signaling. The award funds mechanistic research on how IL17 cytokine signaling in hepatocytes and myeloid cells, particularly neutrophils, suppresses anti-tumor immune responses and creates metastasis-permissive niches in the liver....
- The National Cancer Institute awarded the Institute For Systems Biology $555,592 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop AI-driven infrastructure for integrating and analyzing cancer datasets and identifying cancer risk factors. The recipient will construct a multi-modal, harmonized resource for the tumor microenvironment featuring an AI-powered spatial search tool. Using spatial datasets from the Human Tumor Atlas Network (HTAN), the...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $627,733 in project grant funding on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the molecular mechanisms by which itaconate suppresses CD8+ T cell-mediated anti-tumor immunity in the tumor microenvironment. The funded research characterizes how immune-suppressive myeloid cells secrete itaconate—a metabolite derived from the Krebs cycle intermediate cis-aconitate by the enzyme IRG1—and...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $743,264 on June 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to integrate high-resolution elemental mapping with spatial transcriptomics to analyze metal-based pathways in tumor growth and metastasis. The project grant (R37CA299857) extends through May 31, 2031, with performance at Cedars-Sinai's West Hollywood, California location. The research addresses a critical gap in understanding...
- The National Cancer Institute awarded The Jackson Laboratory $452,458 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to advance and validate single-cell long-read sequencing for cancer molecular profiling. The project develops and validates enhanced tools for single-cell long-read isoform transcriptomics (SCLR-SEQ) to map and analyze full-length spliced isoforms at single-cell resolution in tumor samples. The work addresses technical gaps in current approaches,...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $432,050 on August 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop peptide-MHC pseudotyped retroviral vectors for in vivo gene delivery to antigen-specific T cells as a novel cancer immunotherapy approach. The work addresses a gap in current cancer immunotherapies by combining attributes of CAR-T cell therapies with tumor-infiltrating lymphocyte and immune checkpoint blockade...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $368,294 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period September 1, 2025 through August 31, 2028. This award supports the development of next-generation platforms for interrogating T cell receptor (TCR) specificity to identify and detect tumor antigens at the protein level. The project addresses a critical bottleneck in cancer...